Enliven Therapeutics Statistics
Total Valuation
ELVN has a market cap or net worth of $3.56 billion. The enterprise value is $2.67 billion.
| Market Cap | 3.56B |
| Enterprise Value | 2.67B |
Important Dates
The last earnings date was Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ELVN has 73.60 million shares outstanding. The number of shares has increased by 25.73% in one year.
| Current Share Class | 73.60M |
| Shares Outstanding | 73.60M |
| Shares Change (YoY) | +25.73% |
| Shares Change (QoQ) | +17.85% |
| Owned by Insiders (%) | 2.69% |
| Owned by Institutions (%) | 103.18% |
| Float | 60.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.05 |
| P/TBV Ratio | 4.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 45.95, with a Debt / Equity ratio of 0.00.
| Current Ratio | 45.95 |
| Quick Ratio | 45.41 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -16.77% and return on invested capital (ROIC) is -12.49%.
| Return on Equity (ROE) | -16.77% |
| Return on Assets (ROA) | -12.19% |
| Return on Invested Capital (ROIC) | -12.49% |
| Return on Capital Employed (ROCE) | -15.42% |
| Weighted Average Cost of Capital (WACC) | 6.25% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.75M |
| Employee Count | 65 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +145.98% in the last 52 weeks. The beta is 0.36, so ELVN's price volatility has been lower than the market average.
| Beta (5Y) | 0.36 |
| 52-Week Price Change | +145.98% |
| 50-Day Moving Average | 46.65 |
| 200-Day Moving Average | 43.72 |
| Relative Strength Index (RSI) | 56.11 |
| Average Volume (20 Days) | 1,601,448 |
Short Selling Information
The latest short interest is 9.33 million, so 12.68% of the outstanding shares have been sold short.
| Short Interest | 9.33M |
| Short Previous Month | 10.36M |
| Short % of Shares Out | 12.68% |
| Short % of Float | 15.34% |
| Short Ratio (days to cover) | 5.98 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -135.36M |
| Pretax Income | -113.48M |
| Net Income | -113.48M |
| EBITDA | -135.28M |
| EBIT | -135.36M |
| Earnings Per Share (EPS) | -$1.69 |
Balance Sheet
The company has $884.35 million in cash and $1.32 million in debt, with a net cash position of $883.04 million or $12.00 per share.
| Cash & Cash Equivalents | 884.35M |
| Total Debt | 1.32M |
| Net Cash | 883.04M |
| Net Cash Per Share | $12.00 |
| Equity (Book Value) | 876.95M |
| Book Value Per Share | 11.92 |
| Working Capital | 875.28M |
Cash Flow
In the last 12 months, operating cash flow was -$66.22 million and capital expenditures -$193,000, giving a free cash flow of -$66.41 million.
| Operating Cash Flow | -66.22M |
| Capital Expenditures | -193,000 |
| Depreciation & Amortization | 80,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -66.41M |
| FCF Per Share | -$0.90 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELVN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -25.73% |
| Shareholder Yield | -25.73% |
| Earnings Yield | -3.49% |
| FCF Yield | -1.87% |
Analyst Forecast
The average price target for ELVN is $74.33, which is 53.86% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $74.33 |
| Price Target Difference | 53.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |